Medicure Inc. (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company's primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company's United States subsidiary, Medicure Pharma, Inc. AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS). The Company is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD). The Company has completed Phase IIa stage of development for TARDOXAL. The Company is also developing Transdermal AGGRASTAT, a cure for acute cardiology. Transdermal AGGRASTAT is in preclinical-stage of development.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: CVE:MPH
- CUSIP: N/A
- Web: www.medicure.com/
Capitalization:- Market Cap: C$125.38 million
- Outstanding Shares: 15,633,000
Average Prices:- 52 Week Range: C$5.48 - C$10.67
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: N/A
Sales & Book Value:- Annual Revenue: C$53.05 million
- Price / Sales: 2.36
- Book Value: C$2.12 per share
- Price / Book: 3.78
Profitability:- EBIDTA: C$13.98 million
- Net Margins: 6.66%
- Return on Equity: 16.97%
- Return on Assets: 2.87%
Misc:- Average Volume: 5,792 shs.
- Short Ratio: 1.69
Frequently Asked Questions for Medicure (CVE:MPH)
What is Medicure's stock symbol?
Medicure trades on the Canadian Venture Exchange (CVE) under the ticker symbol "MPH."
How were Medicure's earnings last quarter?
Medicure Inc (CVE:MPH) announced its quarterly earnings results on Wednesday, May, 24th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by $0.37. The firm earned $8.71 million during the quarter, compared to analyst estimates of $14.50 million. Medicure had a net margin of 6.66% and a return on equity of 16.97%. View Medicure's Earnings History.
When will Medicure make its next earnings announcement?
Who are some of Medicure's key competitors?
Some companies that are related to Medicure include Victoria Gold Corp (VIT), Copper Mountain Mining Co.. (CMMC), Input Capital Corp (INP), BSM Technologies (GPS), Conifex Timber (CFF), Orezone Gold Corp (ORE), Titanium Co. (TIC), Madalena Energy (MVN), Strategic Oil & Gas Ltd (SOG), Pan Orient Energy Corp. (POE), Canamax Energy Ltd (CAC), Atico Mining Corp (ATY), Mosaic Capital Corp (M), Ikkuma Resources Corp (IKM), Luna Gold Corp (LGC), Atacama Pacific Gold (ATM), Africa Energy Corp (AFE) and C-Com Satellite Systems (CMI).
Who are Medicure's key executives?
Medicure's management team includes the folowing people:
- Albert D. Friesen Ph.D., Chairman of the Board, President, Chief Executive Officer
- James F Kinley CA, Chief Financial Officer, Secretary
- Brent Fawkes, Director
- Gerald P. McDole, Independent Director
- Arnold Naimark, Independent Director
- Peter Quick, Independent Director
How do I buy Medicure stock?
Shares of Medicure and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Medicure's stock price today?
One share of Medicure stock can currently be purchased for approximately C$8.02.
MarketBeat Community Rating for Medicure (CVE MPH)MarketBeat's community ratings are surveys of what our community members think about Medicure and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Medicure (CVE:MPH) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Medicure (CVE:MPH)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 5/4/2016 | M Partners | Reiterated Rating | Buy | |  |
| 1/12/2016 | Mackie | Boost Price Target | Buy | C$8.00 | |
(Data available from 9/23/2015 forward)
Earnings History for Medicure (CVE:MPH)Earnings History by Quarter for Medicure (CVE MPH)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/8/2017 | | | | | | | | |
| 5/24/2017 | | C$0.04 | C($0.33) | C$14.50 million | C$8.71 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Medicure (CVE:MPH)2017 EPS Consensus Estimate: $0.96
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | $0.09 | $0.09 | $0.09 |
| Q2 2017 | 1 | $0.27 | $0.27 | $0.27 |
| Q3 2017 | 1 | $0.29 | $0.29 | $0.29 |
| Q4 2017 | 1 | $0.31 | $0.31 | $0.31 |
(Data provided by Zacks Investment Research)
Dividend History for Medicure (CVE:MPH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Medicure (CVE:MPH)Insider Trades by Quarter for Medicure (CVE:MPH)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/3/2017 | Graeme William Merchant | Insider | Buy | 1,000 | C$7.07 | C$7,070.00 | |
| 5/2/2017 | Albert David Friesen | Director | Buy | 1,100 | C$7.59 | C$8,349.00 | |
| 3/17/2016 | Albert David Friesen | Director | Buy | 1,100 | C$5.55 | C$6,105.00 | |
| 3/16/2016 | Graeme William Merchant | Insider | Buy | 1,650 | C$6.40 | C$10,560.00 | |
| 3/11/2016 | Graeme William Merchant | Insider | Buy | 1,500 | C$6.30 | C$9,450.00 | |
| 3/8/2016 | Graeme William Merchant | Insider | Sell | 6,300 | C$7.01 | C$44,163.00 | |
| 9/9/2015 | Elliott International Capital | Insider | Sell | 1,426,002 | C$2.98 | C$4,249,485.96 | |
| 1/7/2015 | Albert David Friesen | Director | Buy | 2,900 | C$2.01 | C$5,829.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Medicure (CVE:MPH)
Latest Headlines for Medicure (CVE:MPH)
| Source: |
|
Medicure (MPH) Chart for Saturday, September, 23, 2017
